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ABSTRACT 
Cadmium is an environmental contaminant which accumulates in the 
kidney and can potentially affect human health at relatively low 
concentrations. Biomarkers such as cadmium in urine or blood are 
normally used to assess the body burden of cadmium. We studied the 
relationship between cadmium in urine, blood, and kidney by using 
109 healthy environmentally exposed kidney donors. The variability in 
urinary cadmium excretion, its interpretation, and effects on the study 
design were further examined using repeated urinary samples from 30 
non-smoking healthy men and women. The results showed a strong 
association between cadmium in urine and kidney (rp=0.7), with an 
excretion corresponding to a biological half-time of about 30 years. A 
kidney cadmium of 25 µg/g corresponded to a urinary cadmium of 
0.42 µg/g creatinine (i.e. a urine to kidney ratio of 1:60). Previous 
estimates of the urine to kidney cadmium ratio (1:20) may thus 
underestimate the kidney cadmium at low urinary cadmium excretion. 
On average, 70% of the urinary cadmium excretion could be explained 
by kidney cadmium. Urinary cadmium excretion was also affected by 
cadmium in blood and urinary albumin excretion. There was a 
circadian rhythm in the urinary cadmium excretion over 24h, affecting 
both the interpretation of urinary cadmium measures and the 
appropriate study design. There was an association between urinary 
cadmium and urinary proteins within individuals. Hence, when urinary 
cadmium is used as a biomarker for cadmium body burden, normal 
short-term variability in renal function may result in an overestimation 
of the nephrotoxicity of cadmium. 
 
Keywords: Cadmium, urine, blood, kidney, biological half-time, variability, 
biomarkers, determinants, study design 
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 SAMMANFATTNING PÅ SVENSKA 
Kadmium finns i vår miljö främst till följd av industriella utsläpp och 
från användning av kadmiuminnehållande konstgödsel och 
avloppsslam. Kadmium tas upp från kosten och från tobaksrök, har en 
lång halveringstid i kroppen (decennier) och ansamlas främst i njuren. 
Traditionellt har man sett skador på njurarna som den främsta risken 
vid en långvarig låg kadmiumexponering. Kadmium i urin har ansetts 
vara ett bra mått på halten av kadmium i njure men det har inte funnits 
tillräckligt med studier från levande människor med låg 
kadmiumexponering. I avhandlingen har sambandet mellan kadmium i 
njure, urin och blod studerats med hjälp av prover insamlade från 109 
levande njurdonatorer och halveringstiden för kadmium i njure har 
beräknats. Dessutom har variationen i kadmium- och proteinutsöndring 
i urin studerats hos 30 individer som lämnat upprepade urinprov under 
två dygn. Faktorer som påverkar tolkningen av urinkadmium samt 
lämplig studiedesign har även studerats. 
Resultaten visar att det finns ett starkt samband (rp=0,7) mellan 
kadmium i njure och urin, och utifrån urinutsöndringen kan 
halveringstiden för kadmium i njure skattas till cirka 30 år. Ett 
njurkadmium på 25 µg/g motsvarar ett urinkadmium på 0,42 µg/g 
kreatinin, vilket ger en lägre kvot mellan urin- och njurkadmium (1:60) 
jämfört med tidigare utförda vetenskapliga studier (1:20). Detta 
betyder att den tidigare bedömningen av sambandet mellan urin- och 
njurkadmium underskattar njurkadmium vid låga urinkadmiumnivåer.  
Studien av individerna med upprepade urinprover visar en tydlig 
dygnsvariation i kadmiumutsöndring, vilket man bör ta hänsyn till när 
man planerar en studie. Det fanns även ett tydligt samband mellan 
urinkadmium och urinproteiner inom individer (t.ex. över ett dygn) 
vilket talar för att de samband mellan urinkadmium och urinprotein vid 
låga kadmiumnivåer, som tidigare tolkats som en skadlig effekt på 
njuren av kadmium, istället kan bero på naturliga variationer i 
utsöndring av kadmium och proteiner. 
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1 INTRODUCTION 
As with most environmental contaminants, information on the health 
effects of cadmium was first derived from settings with occupational 
or high environmental exposures to cadmium. Early reports of kidney 
damage from zinc production (probably caused by cadmium exposure) 
date back to the 19
th
 century (Seiffert 1897), and adverse effects of 
cadmium on the human kidney have been demonstrated in 
occupational settings with high cadmium exposure since the late 1940s 
(Friberg 1950).  
 
One of the earlier reports of health effects in environmentally exposed 
populations was the itai-itai disease, a severe disease manifested by 
tubular and glomerular dysfunction and bone injury consisting of a 
combination of osteomalacia and osteoporosis. The itai-itai disease 
was found to be caused by intake of rice, locally grown on fields in 
Japan with high levels of cadmium pollution from nearby zinc mines 
(Hagino and Kono 1955). Since then, a large number of studies have 
found health effects of cadmium exposure in environmentally exposed 
populations, without specific industrial exposures and at relatively low 
cadmium exposures (Åkesson et al. 2005; Chen et al. 2006; de Burbure 
et al. 2006; Hong et al. 2004; Järup et al. 2000; Olsson et al. 2002).  
 
In contrast to many other contaminants in our environment, cadmium 
exposure may not be decreasing (EFSA 2009; Järup et al. 1998; Vahter 
1982; WHO 2007), except in some highly contaminated areas. Much 
attention has therefore been drawn to studies of cadmium exposure in 
the environmentally exposed population during the last couple of 
decades.  
 
This thesis focuses on the application and interpretation of biomarkers 
of cadmium exposure, especially in studies of kidney effects, in the 
environmentally exposed population with low-level cadmium 
exposure. 
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1.1 Environmental exposure to cadmium 
The diet is the main source of cadmium exposure in the 
environmentally exposed population, though for smokers, tobacco 
consumption is also an important route of exposure (EFSA 2009; Järup 
et al. 1998; Nordberg et al. 2007; WHO 2011). The soil on agricultural 
farm fields is contaminated with cadmium through airborne deposition 
from industrial activities and from the use of sewage sludge or 
cadmium-containing fertilizers, and cadmium is accumulated in the 
crops (EFSA 2009; Järup et al. 1998; Nawrot et al. 2010; Nordberg et 
al. 2007; Prozialeck and Edwards 2010; Satarug et al. 2010; WHO 
2007). Cadmium is generally present in all foods but the concentration 
varies to a great extent, depending on the type of food and level of 
environmental contamination. High levels of cadmium are found in 
shellfish, offal such as liver and kidney, and certain seeds. Food from 
plants generally contains more cadmium compared to meat, eggs, and 
dairy products; and plants such as rice, wheat, potatoes, root 
vegetables, and green leafy vegetables contain more cadmium than 
other plants (EFSA 2009; Järup and Åkesson 2009; Sand and Becker 
2012; WHO 2011). 
 
Uptake, distributions and excretion of cadmium in 
humans 
In humans, the gastrointestinal cadmium absorption after ingestion is 
3-5%, while cadmium absorption from inhalation is 10-50% (EFSA 
2009; Nawrot et al. 2010; Nordberg et al. 2007; Prozialeck and 
Edwards 2010; Satarug et al. 2010; WHO 2007). The absorption of 
cadmium is related to iron status, and is generally higher in women 
than in men (Berglund et al. 1994; Flanagan et al. 1978; Julin et al. 
2011; Vahter et al. 1996). After uptake, cadmium in blood is bound to 
albumin and metallothionein. The small cadmium-metallothionein 
complex is filtered in the renal glomerulus, reabsorbed in the tubular 
cells, and accumulated in the kidney with a biological half-time 
ranging from 10 to 30 years (EFSA 2009; Järup and Åkesson 2009; 
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Nawrot et al. 2010; Nordberg et al. 2007; WHO 2007; Åkesson et al. 
2014). Approximately 50% of the total cadmium body burden is 
accumulated in the kidney, and so kidney cadmium and cadmium body 
burden are often referred to each other (EFSA 2009; Järup and 
Åkesson 2009; Nawrot et al. 2010; Nordberg et al. 2007; Åkesson et 
al. 2014). Absorbed cadmium is excreted in urine and faeces. Thus, 
urinary cadmium and blood cadmium are widely used as biomarkers to 
assess the body burden of cadmium in the environmentally exposed 
population (Järup et al. 1998; Nordberg et al. 2007).  
1.2 Human health effects from 
environmental cadmium exposure 
Until now, the main adverse effect of cadmium exposure in the 
environmentally exposed population has been considered to be renal 
tubular damage, measured as an increased urinary excretion of low 
molecular weight proteins such as beta-2-microglobulin, alpha-1-
microglobulin, and retinol-binding protein (EFSA 2009; Järup and 
Åkesson 2009; Järup et al. 1998; Nawrot et al. 2010; Nordberg et al. 
2007; Prozialeck and Edwards 2010; Satarug et al. 2010; WHO 2007; 
Åkesson et al. 2014). However, other cadmium-related effects, mainly 
bone effects but also an increased risk of lung cancer and oestrogen-
dependent cancers, have been seen in recent years (Åkesson et al. 
2008; EFSA 2009; Engström et al. 2011; Engström et al. 2012; Järup 
and Åkesson 2009; Julin et al. 2012; Nawrot et al. 2010; Satarug et al. 
2010; Thomas et al. 2011; Åkesson et al. 2014).  
 
Current health risk assessments, based on kidney effects, have shown 
an impaired renal tubular reabsorptive function when urinary cadmium 
concentration exceeds 4 µg/g creatinine (EFSA 2009; Järup and 
Åkesson 2009; Nordberg et al. 2007; WHO 2011; Åkesson et al. 
2014). However, these adverse effects have recently been seen even at 
lower levels of cadmium exposure, including those occurring in most 
environmentally exposed populations (Åkesson et al. 2005; Chen et al. 
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2006; de Burbure et al. 2006; Hong et al. 2004; Järup et al. 2000; 
Olsson et al. 2002). Still, the causality of these associations between 
urinary cadmium and urinary protein excretions has been questioned, 
both before and after the studies included in this thesis were carried 
out, because of possible confounding by smoking or physiological 
sources of variability (Bernard 2008; Chaumont et al. 2010; Chaumont 
et al. 2012; Chaumont et al. 2013; Haddam et al. 2011; Åkesson et al. 
2014). Thus, it is still a point of discussion whether or not kidney 
effects are the most critical effect of cadmium in the environmentally 
exposed population, and if effects on the kidney (i.e. an increased 
excretion of low molecular weight proteins in urine) may occur at very 
low levels of cadmium exposure.  
1.3 Biomonitoring of environmental 
cadmium exposure  
Assessing the cadmium body burden in humans requires the use of 
biomarkers of exposure. An ideal biomarker should be non-invasive, 
easily accessible, and well documented in terms of the relationship 
between the biomarker and the body burden and factors which might 
affect the interpretation of the biomarker (Nordberg et al. 2007).  
Cadmium in urine is widely used as a biomarker for long-term 
cadmium exposure, while blood generally is used for assessment of 
short-term exposure (EFSA 2009; Järup et al. 1998; Nawrot et al. 
2010; Nordberg et al. 2007; Åkesson et al. 2014). However, for 
environmentally exposed populations, with only small variations in 
their cadmium exposure, cadmium in blood will also represent the 
long-term cadmium exposure (Järup et al. 1998). 
 
Ideally, the 24h urinary excretion should be used (Nawrot et al. 2010; 
Nordberg et al. 2007), but the collection of 24h urine samples is 
laborious and the risk of incomplete or contaminated samples is great. 
Spot urine samples are more feasible, and studies have shown a close 
relationship between urinary 24h cadmium excretion and cadmium 
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measured in spot urine samples (Berlin et al. 1985). However, as for all 
biomarkers in spot urine, the urinary cadmium concentration needs to 
be adjusted for dilution. This is often done by using the creatinine 
concentration in the urine sample (cadmium concentration to creatinine 
concentration ratio), as creatinine is assumed to be excreted at a 
constant rate, or by using the specific gravity of the urine sample 
(Berlin et al. 1985; Suwazono et al. 2005; Trevisan et al. 1994). If the 
excretion time and total volume of the urine sample are known, the 
cadmium excretion rate can also be used (Nordberg et al. 2007). The 
different methods for adjusting urinary cadmium for dilution all have 
their qualities, but the most suitable adjustment method for urinary 
cadmium concentrations in spot urine samples needs to be evaluated 
depending on the aim of the study.  
1.4 Variability in cadmium biomarkers and 
implications for study design 
When cadmium biomarkers are used in epidemiological studies, 
another important factor is the variability between and within 
individuals (Li et al. 2010; Lin et al. 2005; Rappaport and Kupper 
2008). The biomarker should reflect the individual exposure and body 
burden. A preferred biomarker has a large variation between 
individuals with different mean levels (i.e. there is a close relation 
between the biomarker and the body burden). It is also important to 
have biomarkers with low variation within individuals (i.e. stable 
levels between repeated samples from the same individual), since most 
assessments are based on single measurements.  
 
The biological half-time of a biomarker in the human body has been 
shown to affect the total variability, with slower elimination leading to 
a decreased variability in the biomarker (Lin et al. 2005). However, a 
biomarker with a long biological half-time and a stable long-term level 
may still be affected by different sources of variability which will 
induce short-term variability (variability within a day or a week). This 
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short-term variability will affect the interpretation of the measured 
biomarker in a study. 
 
Potential sources of short-term variation in repeated measurements of 
cadmium biomarkers in urine include natural physiological variations 
(e.g. variations in urinary flow rate, excretion rate, or absorption rate), 
the choice of sampling time (time of the day), and the method used to 
adjust the urinary cadmium concentration for diuresis. Another 
potential source of variability is the analytical method, which will be 
included in the within-individual variance. The analytical variability is 
generally small (Mason et al. 1998), but the analytical method needs to 
be validated. Factors affecting the analysis, such as molybdenum 
oxide-based interference (Jarrett et al. 2008; Suzuki et al. 2008), may 
have a large impact and need to be taken into consideration and 
corrected for.  
 
The relationship between the within- and between-individual 
variability for a given biomarker might attenuate the result of an 
epidemiological study (Rappaport and Kupper 2008), and so sources of 
variation need to be investigated and controlled for in the study design. 
1.5 Relationship between cadmium in 
kidney and cadmium in urine and blood 
One of the most important criteria in evaluating the optimal biomarker 
of cadmium body burden is the relationship between body burden and 
the biomarker. Close relationships between cadmium in kidney, urine, 
and blood are anticipated at steady state. Attempts have been made to 
quantify the relationship using in vivo measurements such as X-ray 
fluorescence (Börjesson et al. 1997; Börjesson et al. 2001; 
Christoffersson et al. 1987; Nilsson et al. 2000; Nilsson et al. 1995) 
and neutron activation (Ellis et al. 1979; Mason et al. 1999; Roels et al. 
1981) or by autopsy studies (Orlowski et al. 1998; Satarug et al. 2002). 
However, the current in vivo techniques are not sensitive enough to 
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investigate the relationship between kidney cadmium and cadmium in 
blood and urine at low-level cadmium exposures (Nilsson et al. 2000; 
Nilsson et al. 1995). Thus, most of the current information originates 
from studies of occupationally exposed workers, which may not be 
representative for environmentally exposed individuals with a lower 
level of cadmium body burden and a different exposure pattern. In 
addition, autopsy studies of environmentally exposed individuals may 
not be representative of the healthy part of the population, and 
cadmium levels in urine and blood may change post mortem. 
Moreover, data concerning diet and smoking habits may be uncertain 
in these studies. 
 
Reviews of the existing data (occupational and environmental 
exposure) show that a urinary cadmium concentration of 2.5 µg/g 
creatinine corresponds to a kidney cadmium concentration of about 50 
µg/g; that is, a urine to kidney cadmium ratio of about 1:20, if a linear 
relationship between kidney cadmium and cadmium in urine is 
assumed (EFSA 2009; Järup et al. 1998; Nordberg et al. 2007). 
However, there is still a need for more information regarding the 
relationship between kidney cadmium and cadmium in urine at the 
lower cadmium levels which occur in environmentally exposed 
populations without any industrial sources of exposure. 
Biomonitoring of Cadmium 
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2 AIMS OF THIS THESIS 
The overall aim of this thesis was to improve the existing methods for 
biomonitoring and the interpretation of urinary cadmium levels in 
studies of environmentally exposed individuals, with a special 
reference to studies of kidney effects. 
 
The specific aims were: 
 
To study the association between cadmium in kidney, urine, and blood 
by: 
- determining the relationship between cadmium in 
kidney and cadmium in urine and blood (Paper I) 
- determining factors affecting the relationship between 
cadmium in kidney, urine, and blood (Paper I) 
- determining the excretion rate and thereby the 
biological half-time of cadmium in kidney (Paper I) 
 
To improve the interpretation of cadmium measured in urine by: 
- studying the causality of an association between 
urinary cadmium and urinary protein excretion at low 
cadmium levels (Paper II) 
- studying the effect of molybdenum oxide-based 
interference on urinary cadmium analysis when certain 
inductively coupled plasma mass spectrometry (ICP-
MS) methods are used (Paper III) 
- studying short-term variations in urinary cadmium 
excretion during the day (Paper IV) 
 
To evaluate how these results should affect the study design by: 
- assessing how variability in urinary cadmium excretion 
should affects sample sizes in studies (Paper IV) 
- assessing which measure best represents cadmium in 
kidney/body burden (Papers I-IV) 
Magnus Åkerström 
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3 MATERIALS AND METHODS 
3.1 Study populations and study designs 
Two different study populations, both environmentally exposed to 
cadmium, were used in this thesis. Background data for the study 
participants in each study population are shown in Table 1. Different 
exclusion criteria were used in the different papers, depending on the 
aim of the study, as indicated below. When a subpopulation of the total 
study population was used (Papers I & IV), no substantial difference 
were seen between the subgroup and their corresponding total study 
population. For detailed information, see Papers I-IV. 
 
Informed consent was obtained from all study participants, and the 
studies were approved by the Ethics Committee of the University of 
Gothenburg. 
 
Table 1. Background data for study populations 1 & 2 
Variables   
Study population 1 
(Papers I & III) 
  
Study population 2 
(Papers II & IV) 
Study participants, N
a
 152   30 
 Women  
87 
 
15 
 Men 
65 
 
15 
Median age, years (range) 50 (24-70) 
 
39 (23-59) 
 
Women  49 (24-64) 
 
39 (23-56) 
 
Men 51 (30-70) 
 
35 (23-59) 
Ever smokers, N
a
 (Current smokers, %) 91
b
 (40) 
 
0 (0) 
 
Women  53
b
 (36) 
 
0 (0) 
 
Men 38
b
 (45) 
 
0 (0) 
Median BMI, kg/m
2
 (range) 25 (18-32) 
 
24 (19-29) 
 
Women  25 (18-32) 
 
23 (19-29) 
 
Men 25 (22-32) 
 
25 (21-29) 
aN=number of samples,  bMedian pack-years (range): 13 (0.4-51) for all smokers, 13 (1.2-36) for 
women, and 12 (0.4-51) for men 
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Study population 1 (Papers I & III) 
Living healthy kidney donors were recruited between 1999 and 2005 
to a study of heavy metal concentrations in kidney, blood, and urine 
(the TINA study) (Barregard et al. 2010). Of the 167 eligible donors 
admitted at the Department of Transplantation and Liver Surgery at 
Sahlgrenska University Hospital for kidney transplantation, 152 (81%) 
participated after giving their informed consent. Occupational history 
and smoking habits were collected through a structured interview.  
 
All donors had been examined with routine tests less than one year 
before the transplantation, in order to be accepted as a kidney donor. 
The donors were admitted to the hospital 1-2 days before the 
transplantation. Blood samples were taken in 10 mL Venoject II tubes 
(Terumo Europe, Leuven, Belgium), and separate 24h and timed 
overnight urine samples were collected in pre-washed polypropene 
bottles and transferred to 14 mL polypropene tubes (Sarstedt, 
Nümbrecht, Germany). A small part of a reference kidney cortex 
biopsy, taken as a routine procedure during the transplantation, was 
available for metal analysis and handled as described in Barregard et al 
(2010). The numbers of complete samples are shown in Figure 1. 
Figure 1. Number of collected, missing, excluded, and remaining kidney biopsies, 
and urine and blood samples in study population 1 (Paper I, Figure 1) 
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In Paper I, calculations were performed both for all data and for the 
subgroup with a kidney biopsy, while Paper III was based on the urine 
samples only. Urine samples with a 24h urine volume above 5000 mL 
or below 700mL were regarded as not representative, and were 
excluded from both studies. In addition, very diluted or concentrated 
samples (urinary creatinine <0.3 g/L or >3.0 g/L and specific gravity 
<1.010 or >1.030) were excluded in Paper I in order to assess the 
association between kidney cadmium and cadmium in urine under 
normal conditions. These samples were however used in Paper III, 
since we wished to study the effect of molybdenum oxide-based 
interference over the entire range of data. 
Study population 2 (Papers II & IV) 
Thirty non-smoking healthy participants (15 men and 15 women, all 
free from diabetes, hypertension, and kidney disease) were recruited 
for a study of short-term variability in urinary protein excretions 
(Andersson et al. 2008).  The study participants were recruited in 2006 
among the staff at the Department of Occupational and Environmental 
Medicine at Sahlgrenska University Hospital and among students at 
the University of Gothenburg. Each participant filled out a 
questionnaire concerning age, weight, height, diseases, and 
medications.  
 
Participants provided timed urine samples during two separate days, 
mostly within one week. Each day, they were asked to provide urine 
samples at six fixed time points: 09:30 (second morning sample), 
12:00, 14:30, 17:30, 22:00, and overnight (first morning sample). 
Detailed information was given to ensure complete 24h urine 
sampling. All study participants provided 12 urine samples each, 
except one woman, who only provided samples during one day (six 
samples).  
 
The samples were transferred to Minisorb tubes (NUNC, Roskilde, 
Denmark) and kept at 4°C until analysis of proteins (albumin and 
alpha-1-microglobulin) and creatinine within three days of collection. 
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Aliquots used to determine urinary cadmium were frozen (-20°C) and 
analysed five years later. 
 
In Paper II, all data were used in the statistical analyses to study the 
association between urinary cadmium and protein excretions. In Paper 
IV, when the variability in urinary cadmium excretion was studied, six 
study participants were excluded from the statistical analysis: the 
woman with samples from only one day, another woman with 
repeatedly very low 24h urine excretion (around 500 mL), and four 
participants (1 man and 3 women) for whom more than 50% of the 12 
urinary samples had cadmium levels below the limit of detection. 
3.2 Chemical analyses and data 
transformations 
A short summary of the chemical analyses and data transformations 
follows below; more details can be found in Papers I-IV.   
 
All samples were analysed together with external quality control 
samples, showing satisfactory results, and all sampling material had 
been demonstrated free from cadmium prior to the studies. Samples 
below the limit of detection were assigned the value 
                  
 
 or 
                  
√ 
 depending on the distribution of data (Hornung and 
Reed 1990). Since all urine samples in these studies were timed and 
the volumes were measured, it was possible to calculate urinary flow 
rate, 24h excretions, and urinary excretion rates of cadmium and 
proteins. Urinary concentrations of cadmium and proteins were 
adjusted for dilution by urinary creatinine concentration or specific 
gravity (reference =1.015) (Suwazono et al. 2005).  
Cadmium concentrations in kidney, urine and blood 
Cadmium concentrations in kidney, urine, and blood samples were 
analysed by ICP-MS (Thermo X7, Thermo Elemental, Winsford, UK) , 
in samples diluted ten times (Barany et al. 1997). The analyses were 
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carried out at the Department of Occupational and Environmental 
Medicine, Lund University Hospital. The procedure for analysis of 
cadmium in kidney biopsies has been described elsewhere (Barregard 
et al. 2010).  
 
The dry weight cadmium concentration of the kidney cortex was 
transformed to wet weight concentration by multiplying by 0.18 
(Barregard et al. 1999; Elinder et al. 1990). The kidney weight for each 
participant was estimated from the body surface area (Kasiske and 
Umen 1986). The total amount of cadmium in the kidney was 
calculated by multiplying the estimated kidney weight by the 
concentration of cadmium in the kidney cortex and then dividing by 
1.25 to adjust for the higher cadmium concentration in the cortex 
compared to the rest of the kidney (Svartengren et al. 1986).  
 
The urinary cadmium concentrations were corrected for molybdenum 
oxide-based interference, since molybdenum oxide formed during the 
analysis from the molybdenum naturally present in urine might 
interfere with cadmium isotopes 
111
Cd and 
114
Cd (Jarrett et al. 2008; 
Suzuki et al. 2008). The correction for molybdenum oxide-based 
interference was made by adding molybdenum (500 µg/L) to blank 
urine samples several times in each analytical run, and evaluating the 
formation of molybdenum oxide. Molybdenum was determined in all 
samples, and thus a correction for the molybdenum oxide-based 
interference could be made via the known proportion of molybdenum 
to molybdenum oxide. 
All urine samples in study population 1 were reanalysed in one batch 
2012 since only half of the urine samples had been corrected for 
molybdenum oxide-based interference in the initial analysis. However, 
after reanalysing all the samples from this population (131 24h 
samples and 146 overnight urine samples) it was possible to calculate 
the effect of molybdenum oxide-based interference on the urinary 
cadmium analysis (Paper III).  
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Repeated measurements of specific gravity, in connection with the 
reanalysis, in 20 randomly chosen samples showed no evidence of 
dehydration of the urine samples after being stored in the freezer (-20 
°C) for up to 13 years, when compared to the measurements that were 
carried out in fresh urine. 
Urinary protein and creatinine concentrations, and 
specific gravity 
Two urinary proteins were analysed as a measure of adverse effects on 
the kidney: albumin (Ferraro et al. 2010; Nordberg et al. 2012; 
Nordberg et al. 2009; Åkesson et al. 2014) and the low molecular 
weight protein alpha-1-microglobulin (Åkesson et al. 2005; Bakoush et 
al. 2001; Penders and Delanghe 2004). Urinary albumin (used in 
Papers I, II, & IV) was analysed in both study populations using a 
nephelometric immunochemical method with reagents and calibrators 
from Beckman Coulter (Fullerton, CA, USA). Urinary alpha-1-
microglobulin was analysed in study population 2 and used in Papers 
II & IV. The analysis was performed using the α1-microglobulin 
ELISA kit K6710 (Immundiagnostik AG, Bensheim, Germany).  
 
Urinary creatinine concentration and specific gravity were analysed in 
order to allow adjustment for dilution in cadmium and protein 
concentrations from spot urine samples. Urinary creatinine 
concentrations were analysed in fresh urine using two different 
methods. All samples in study population 2 and three out of four 
batches in study population 1 were analysed using the Jaffé method 
(Roche Diagnostics, Mannheim, Germany). The remaining samples in 
study population 1 were analysed with an enzymatic method (Modular 
P and CREAplus R1, R2, Roche/Hitachi, Roche Diagnostics, GmbH, 
Mannheim, Germany).  Specific gravity was determined in fresh urine 
with a Ceti Digit 012 refractometer (Medline, Oxfordshire, UK). 
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3.3 Statistical methods 
Data analyses were performed using version 9.1 of the SAS software 
package (SAS Institute, Cary, NC, USA). Statistical significance was 
determined at p<0.05, and two-sided confidence intervals were used if 
not stated otherwise.  
Mean values of groups, individuals, and sampling times, 
and tests of significant differences (Papers I-IV) 
The mean levels of different biomarkers were not a focus point in this 
thesis, but mostly merely used to describe the study populations. 
Average levels in groups were generally described using arithmetic 
means and ranges on untransformed data.  
 
In Papers II & IV, data consisted of repeated measurements from 30 
study participants. In Paper II, the mean values of urinary cadmium 
and protein excretions were calculated as arithmetic means of the 30 
individual arithmetical means. The mean cadmium excretion was also 
calculated in Paper IV using mixed-effect models (see below) to fully 
account for the repeated sampling. In the graphical presentation of the 
circadian rhythms of urinary cadmium, urinary protein excretion, and 
urinary flow rate in Paper IV, geometric means of individual 
arithmetic means for each time point of sampling were used. 
 
Significant differences between paired samples were tested using a 
paired t-test. Differences between groups were tested for significance 
using the Wilcoxon rank-sum test, since the data were not generally 
normally distributed.  
Correlations, linear regression models, and estimates of 
the biological half-time of cadmium in kidney (Papers I-IV) 
Associations between variables were assessed with correlation 
coefficients (Papers I & II) and linear regression models (Papers I-IV). 
In Paper I, Pearson’s correlation coefficients (rp) were calculated to 
study the linear relationship between kidney cadmium and cadmium 
biomarkers in blood and urine. For the repeated samples in Paper II, 
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Spearman’s correlation coefficients (rs) were calculated within each 
study participant, as data were skewed. The overall mean correlation 
coefficients were calculated by averaging the participant-specific 
correlation coefficients, and tested for significant deviation from zero 
using the Wilcoxon signed-rank test. 
 
In the regression models in Papers I-III, untransformed data were used 
except for urinary protein excretions which were naturally log-
transformed due to a highly skewed distribution in combination with a 
small spread in data.  Differences between regression slopes were 
investigated using the F-test. When backward stepwise elimination was 
used to derive the final models in multiple regression models, p<0.1 
was used as the inclusion criterion if not stated otherwise.  
 
Most of the regression models in Paper I were weighted, since the data 
were not fully homoscedastic, using the weight function 
 
                    
 when the association between kidney cadmium 
and urinary cadmium was studied and when determinants for urinary 
cadmium were calculated using multiple regression models.   
 
Studying the association between urinary cadmium, urinary protein 
excretion, and urinary flow rate in Paper II, we hypothesized that 
physiological changes in urinary protein excretions and urinary flow 
rate would affect urinary cadmium excretion (rather than the opposite), 
and hence chose urinary cadmium as the dependent variable. The 
overall mean regression coefficients for these associations were 
calculated and tested for deviation from zero in the same way as the 
correlation coefficients mentioned above. 
 
In Paper I, the biological half-time (t1/2) of cadmium in kidney was 
estimated using Equation 1, assuming a one-compartment model. 
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The elimination constant (k) was determined from the association 
between the 24h cadmium excretion and the total amount of cadmium 
in kidney. 
Mixed-effect models (Paper IV) 
Mixed-effect models were used on data from study population 2 
(Paper IV), to estimate the between- and within-individual variability 
in the urinary cadmium excretion and to determine factors affecting the 
urinary cadmium excretion (Rappaport and Kupper 2008). Before 
inclusion in the models, the normality of each cadmium measure in 
spot urine, overnight urine, and 24h urine was tested using the Shapiro-
Wilks test to determine whether untransformed or log-transformed data 
should be used in the analyses. Natural log-transformed data were used 
in the mixed-effect models (Equation 2) for all measures, since the 
data were skewed.  
 
                 ∑      
 
                   (2) 
 
Xij is the exposure level for the i
th
 person in the j
th
 measurement, µY is 
the fixed mean (log-transformed) exposure level for the population, bi 
is the random effect of the i
th
 person, and eij is the random error for the 
j
th
 measurement of the i
th
 person. The model also contains additional 
fixed effects for U covariates (determinants and interaction terms) C1, 
C2, …, Cu; ∂u are regression coefficients representing the U covariates. 
The random effects, bi and eij, are assumed to be mutually independent 
and normally distributed with means of zero. 
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Before applying the mixed-effects model to each measure of cadmium 
in urine, a likelihood test was used to assess whether a common fixed 
mean exposure level and common variances could be used for men and 
women. The between- and within-individual variance components 
(   
   and    
   were calculated for each measure using a model 
(Equation 2) which contained only random effects, a global mean, and 
gender (Model 1A, null model). The natural-scale mean exposure level 
was estimated as      
         
   where   
      
      
 . Estimates 
of 95% between- and within-individual fold ranges (        and 
      ) were determined for each measure of urinary cadmium 
excretion using Model 1A, where          
        and        
         . The estimated ratio of the between-individual biomarker 
variance to total observed variance (the intraclass correlation, ICC) 
was calculated as      
   
 
  
  (Rappaport and Kupper 2008). 
 
Determinants of urinary cadmium excretion were investigated in study 
population 2 (Paper IV) using Model 1B for spot urine samples and 
Model 1C for overnight urine and 24h urine samples. These models 
were constructed by adding more covariates to model 1A: sampling 
time, age, body mass index (BMI), urinary flow rate, and urinary 
protein excretions (as well as their interaction terms with gender). 
Covariates with a Spearman correlation coefficient above 0.5 were not 
included in the models simultaneously in order to avoid 
multicollinearity. The final models were achieved by removing non-
significant determinants by backwards stepwise elimination. 
Calculation of group sizes (Paper IV) 
The effect of the variability in urinary cadmium excretion on the 
appropriate study design was investigated in study population 2 (Paper 
IV) by calculating the number of samples required to achieve a certain 
accuracy for two different types of study: epidemiological 
individually-based studies of log-transformed exposure to log-
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transformed response relationships, and studies of differences in the 
mean level of cadmium exposure between groups. 
For the first type of study, the degree of attenuation (i.e. the ratio 
between the regression coefficient estimated in the study, βest, and the 
true regression coefficient, βtrue) for a given measure of urinary 
cadmium excretion was determined from estimated variance 
components in Model 1A (Equation 2) using the equation: 
 
   
    
     
     
 
 
                           (3) 
 
where the bias is 1-b,    
   
 
   
 , and n is the number of repeated 
measurements per individual (Brunekeef et al. 1987; Heederik et al. 
1991). 
 
For the second type of study, the number of samples per group (m) 
required in order to detect a statistically significant (p<0.05) difference 
of 10%, 25%, 50%, or 100% respectively in the geometric mean values 
with a statistical power (P) of 80% was calculated using the total 
variance and the ICC derived from Equation 2, with just a global 
mean, and the following formula (Li et al. 2010): 
 
   (     )
 
  
 [          ]                (4) 
 
where Zα and Zβ are the α
th
 and βth percentiles of a standard Gaussian 
distribution (one-tailed), α is the desired type I error (α =0.05), β is the 
desired type II error (β =1-P), n is the number of samples per 
individual (1, 2 or 3), and d is the difference in means of log-
transformed concentration between the two groups (Li et al. 2010).  
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4 RESULTS 
This section is a summary of the main results; for further details the 
reader is referred to the separate papers (Papers I-IV). Some additional 
results which do not appear in the papers have also been included. 
4.1 Mean cadmium concentrations in 
kidney, urine, and blood in the two 
study populations (Papers I-IV) 
The mean kidney cortex cadmium concentration was 15.0 µg/g and the 
mean total amount of cadmium in the kidney was 3860 µg in the total 
group of study population 1. Mean kidney cortex cadmium 
concentrations were 17.9 µg/g and 10.4 µg/g for ever-smokers and 
never-smokers respectively and 17.1 µg/g and 12.5 µg/g for women 
and men respectively, as described previously (Barregard et al. 2010).  
 
The measures of cadmium in urine and blood in study population 1 and 
2 are summarized in Table 2 (Paper II, Table 1 and Paper III, Table 
1). The urinary cadmium concentrations among participants with a 
kidney biopsy did not differ substantially from those in the total study 
population (Paper I, Table 2). Using a mixed-effect model on the 
repeated measurements of study population 2 showed a urinary 
cadmium concentration in overnight samples (first morning samples) 
of 0.08 µg/g creatinine for men and 0.17 µg/g creatinine for women 
(p=0.009) and a 24h urinary cadmium excretion of 0.18 µg for both 
men and women (Paper IV, Table 1).  
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Table 2.  Mean concentrations and ranges of cadmium in urine and blood for 
study populations 1 & 2 
  
Study population 1  
(Papers I & III) 
  
Study population 2  
(Papers II & IV) 
 Measure N Mean Range   N
a
/n Mean
b
 Range
c
 
Spot urine samples
d
 
       
     U-Cd (µg/L) 146 0.34 0.02-1.9 
 
354/30 0.12 <LOD
e
-1.1 
     U-CdCrea (µg/gC)
f
 146 0.28 0.04-1.1 
 
354/30 0.11 0.01-0.52 
     U-CdSG (µg/L)
g
 146 0.25 0.04-1.0 
 
354/30 0.12 0.01-0.71 
     U-Cd/h (µg/h)
h
 146 0.013 0.002-0.047 
 
354/30 0.007 0.001-0.03 
24h urine samples 
       
     U-Cd (µg/L) 131 0.18 0.02-0.77 
 
 -   -   -  
     U-CdCrea (µg/gC)
f
 131 0.25 0.03-1.0 
 
 -   -   -  
     U-CdSG (µg/L)
g
 131 0.18 0.03-0.66 
 
 -   -   -  
     U-Cd/h (µg/h)
h
 131 0.012 0.002-0.037 
 
30  0.007  0.003-0.02  
     U-Cd/24h (µg) 131 0.30 0.04-0.89 
 
30 0.17 0.06-0.36 
Blood samples 
       
     B-Cd (µg/L) 109 0.51 <LOD
e
-2.9 
 
 -   -   -  
N=number of samples, n=number of individuals 
aOne woman only provided samples over 1 day (6 samples) 
bMean values are calculated as mean of 30 individual means (n) 
cRanges are for all 354 urine samples (N) 
dOvernight urine samples for population 1 and six spot urine samples per day for population 2 
eValues below limit of detection (LOD) were replaced with LOD/2 or LOD/2 in calculations 
according to the distribution of data. 
fConcentrations adjusted for creatinine concentration 
gConcentrations adjusted for specific gravity  
hExcretion rates 
4.2 Associations between cadmium in 
kidney and cadmium in urine and blood 
(Paper I) 
Positive and highly significant correlations were seen between the 
concentration of cadmium in kidney cortex and the concentrations of 
cadmium in urine and blood samples in study population 1 (Paper 1, 
Table 2). The correlation was generally stronger for the measures of 
cadmium in urine (rp= 0.44-0.70, p<0.001 respectively) than for 
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cadmium in blood (rp= 0.44, p<0.001). The correlation coefficient 
increased when urinary cadmium was adjusted for dilution, and 
somewhat higher correlations were seen for 24h urine samples 
compared to overnight urine samples. There was also a relatively 
strong association (rp= 0.63, p<0.001) between the 24h urinary 
cadmium excretion and the total amount of cadmium in the kidney 
(Figure 2). 
 
Figure 2. Association between the 24h urinary cadmium excretion and the total 
amount of cadmium in the kidney. 
The overnight urinary cadmium concentration adjusted for creatinine 
concentration explained more of the total variability (R
2
=0.44) 
compared to the other measures of cadmium in overnight urine 
samples (R
2
=0.31-0.19; Figure 3). According to the linear regression 
model, kidney cortex cadmium levels of 10 and 25 µg/g would 
correspond to an overnight urinary cadmium concentration adjusted for 
creatinine concentration of 0.21 and 0.42 µg/g creatinine, respectively, 
giving a urinary cadmium to kidney cadmium ratio of about 1:60.  
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Figure 3. Associations between kidney cortex cadmium (wet weight) and overnight 
urine and blood cadmium concentrations. Results from linear (unweighted) 
regression models (Paper I, Figure 2) 
A nonlinear relationship was seen between the total amount of urinary 
cadmium excreted in 24h and the total amount of cadmium in kidney 
(Paper I). There was also a significant difference (p<0.001) between 
the slopes for low versus high kidney cadmium concentrations (< 15 
µg/g compared to ≥ 15 µg/g) when weighted regression models 
without intercept were used (Figure 4). The ratio of urinary cadmium 
to kidney cadmium also differed significantly between these two 
groups. 
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Figure 4. Cadmium in urine per 24 h versus total cadmium in kidney using weighted 
regression without intercept for a linear model. Regression lines are included for the 
total dataset and for the subgroups with kidney cadmium below or above 15 μg/g 
(Paper I, Figure 3). 
4.3 Excretion rate and biological half-time 
of cadmium in kidney (Paper I) 
Elimination constants for different models were estimated in study 
population 1 from the association between urinary cadmium per 24h 
and the total amount of cadmium in the kidney using weighted 
regression models (Paper I).  
 
If a straight line equation without intercept was assumed, the estimated 
elimination constant was 0.09×10
-3
; that is, the fraction of the total 
amount of kidney cadmium excreted in urine per 24h was 0.009%. 
According to Equation 1, the estimated biological half-time for 
cadmium in kidney was 21.0 years (95% confidence interval [95% CI]: 
18.9-23.6 years). Separate calculations for kidney cadmium 
concentrations <15 µg/g and ≥ 15 µg/g showed elimination constants 
of 0.11×10
-3
 and 0.07×10
-3
, and biological half-times of 17.9 years 
(95% CI: 15.7-20.8 years) and 26.7 years (95% CI: 23.4-31.1 years), 
respectively. If a straight line equation with an intercept was assumed 
for the total study population, the elimination constant was 0.06×10
-3 
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and the biological half-time was 30.4 years (95% CI: 24.3-40.5 years) 
with an intercept of 0.073 µg/24h. 
 
Since the relationship between urinary cadmium per 24h and the total 
amount of cadmium in the kidney was found to be nonlinear, a 
polynomial model without intercept (U-Cd/24h= 0.11×10
-3
 × K-Cdtot 
– 5.8×10-9 × K-Cdtot2) was used to calculate the biological half-time 
for different kidney cadmium levels, using Equation 1. The estimated 
half-times for kidney cadmium levels of 2000 µg, 4000 µg, and 6000 
µg (approximately corresponding to kidney cadmium concentrations of 
8 µg/g, 15 µg/g, and 23 µg/g, respectively) were 21.2 years, 28.5 years, 
and 43.5 years, respectively. 
4.4 Determinants for urinary cadmium 
excretion (Papers I & IV) 
Determinants for the 24h urinary cadmium excretion were investigated 
in study population 1 using weighted regressions for three different 
linear regression models: one for all participants, one using different 
equations for never- and ever-smokers, and one using different 
equations for low and high kidney cortex cadmium concentrations (< 
or ≥ 15 µg/g) (Paper I). The final models explained about half of the 
total variability using determinants as the total amount of cadmium in 
the kidney, blood cadmium, log-transformed 24h urinary albumin 
excretion, gender, and smoking (Table 3).  
 
Kidney cadmium was a significant determinant for all models. The 
log-transformed 24h urinary albumin excretion was a significant 
determinant for all participants combined, for never-smokers, and for 
those with a kidney cortex cadmium <15 µg/g. Conversely, blood 
cadmium was a significant determinant for ever-smokers and for those 
with a kidney cortex cadmium ≥ 15 µg/g. 
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Table 3. Effects of kidney cadmium, blood cadmium, urinary albumin, 
gender, and smoking on 24h urinary cadmium excretion (Paper I, Table 3). 
 
Model
a
 
Dependent  
variable
b
 
Independent  
variables
c
 
Estimates  
(p-value) 
R
2
 
Correlation
d
  
(p-value) 
Model 1 
   0.71  
(<0.001) All  U-Cd/24h Intercept -0.029 (0.4) 0.60 
      (N=86) K-Cdtot 0.000056 (<0.001) 
  
 
log(U-Alb/24h) 0.045 (0.02) 
  
 
Smoking 0.061 (0.008) 
  
Model 2       
0.73  
(<0.001) Never-
smokers  
U-Cd/24h Intercept -0.0038 (0.09) 0.48 
(N=31)  K-Cdtot 0.000052 (<0.001) 
  
 
log(U-Alb/24h) 0.034 (0.09) 
  
Ever-
smokers 
U-Cd/24h Intercept -0.010 (0.9) 0.42 
 
(N=55)  K-Cdtot 0.000041 (<0.001) 
  
 
B-Cd 0.081 (0.06) 
  
 
Sex -0.070 (0.06) 
  
 
Age 0.0036 (0.05) 
  
Model 3       0.72  
(<0.001) K-Cdconc 
<15 µg/g 
(N=47) 
U-Cd/24h Intercept -0.031 (0.03) 0.52 
 K-Cdtot 0.000062 (<0.001) 
  
 
 log(U-Alb/24h) 0.040 (0.01) 
  
 
Smoking  0.065 (0.006) 
  
   K-Cdconc  
   ≥15 µg/g 
   (N=39) 
U-Cd/24h Intercept -0.012 (0.9) 0.29 
 
 K-Cdtot 0.000058 (0.002) 
  
 
B-Cd 0.12 (0.07) 
  
aModels derived by weighted regressions using backwards elimination from the full model U-
Cd/24h=intercept+K-Cdtot+B-Cd+log(U-Alb/24h)+age+sex+UF+GFR+smoking 
bUnit is µg/24h 
 cUnits as follows: K-Cdtot (µg), U-Alb/24h (mg/24h), smoking (never=0, ever=1), B-Cd (µg/L), sex 
(men=0, women=1), and age (years)  
dPearson correlation between U-Cd/24h and estimated U-Cd/24h per model  
N=number of samples 
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Determinants for urinary cadmium excretion were also investigated for 
spot urine, 24h urine, and overnight urine samples in study population 
2, using two mixed-effects models: Model 1B and Model 1C (Equation 
2, Paper IV). Gender, time point of sampling (for spot urine samples), 
age, urinary flow rate, and protein excretion (mainly urinary albumin) 
were significant determinants for most measures of urinary cadmium 
excretion (Paper IV, Tables 2-3). The covariates explained on average 
41% of the total variance for spot urine samples and 33% for 24h urine 
and overnight urine samples. When time point of sampling was 
removed from model 1B, the total variance increased by an average of 
11% (average difference -4% for between-individual variance and 
+40% for within-individual variance). 
4.5 Association between urinary cadmium 
and urinary proteins within individuals 
(Paper II) 
On average, urinary cadmium excretion was positively associated 
(p<0.001) with both urinary albumin and alpha-1-microglobulin within 
the study participants of study population 2 (Figure 5).  
The associations between urinary cadmium excretion and urinary 
protein excretion were stronger when expressed as urinary excretion 
rates (overall mean rs=0.44 for association with urinary albumin and 
rs=0.33 for urinary alpha-1-microglobulin) and urinary concentrations 
adjusted for specific gravity (overall mean rs=0.37 for urinary albumin 
and rs=0.26 for urinary alpha-1-microglobulin), compared to when the 
urinary excretions were expressed as urinary concentrations adjusted 
for creatinine concentrations (overall mean rs=0.26 for urinary albumin 
and rs=0.21 for urinary alpha-1-microglobulin) (Figure 5).   
 
When both urinary albumin and urinary alpha-1-microglobulin were 
included in the regression models for each study participant, both 
proteins were on average found to significantly predict the urinary 
excretion of cadmium. 
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Figure 5. Distributions of individual Spearman correlation coefficients (rs; A, B) and 
individual regression coefficients (β; C, D) for associations between U-Cd and U-Alb 
(A, C), and U-Cd and U-A1M (B, D), calculated for 30 individual participants. 
Individual values are based on 6 samples per day over 2 days for each participant, 
with 354 total samples (1 participant had 6 samples only). Boxes indicate 10th and 
25th percentiles; dotted line, mean; solid line, median; and whiskers, 75th and 90th 
percentiles across all participants, with dots indicating outliers (Paper II, Figure 2). 
When the urinary flow rate was included in the linear regression 
models between urinary cadmium (dependent variable) and urinary 
proteins (albumin or alpha-1-microglobulin), the overall mean 
regression coefficients for urinary flow rate were significantly larger 
than zero both when expressed as urinary excretion rates and when 
expressed as urinary concentrations adjusted for specific gravity, but 
not when expressed as urinary concentrations adjusted for creatinine 
concentrations (Paper II, Table 3). Similar overall mean regression 
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coefficients for urinary albumin and alpha-1-microglobulin were seen 
in the models with and without inclusion of urinary flow rate. 
4.6 Effect of molybdenum oxide-based 
interference on urinary cadmium 
analysis (Paper III) 
The median reduction of the urinary cadmium concentration was 55% 
in the 24h urine samples and 38% in the overnight urine samples after 
correcting for the molybdenum oxide-based interference (Paper III, 
Figure 1). The reanalysis showed good agreement with initial levels for 
the samples that had already been corrected in the initial analysis.  
4.7 Short-term variations in urinary 
cadmium excretion during the day and 
implications for study design (Paper IV) 
The short-term variability in urinary cadmium excretion was 
investigated in study population 2 (Paper IV) using Model 1A 
(Equation 2). The total variance ranged between 0.20 and 0.62, and the 
between-individual variance dominated the total variability for most 
urinary measures of cadmium. The ICC increased when the urinary 
cadmium concentration was adjusted for dilution and when a specific 
time point of sampling was used (overnight or 24h urine samples 
compared with spot urine samples) (Paper IV, Table 1).  
 
Expressed as fold ranges, 95% of the urinary cadmium excretions for a 
given individual were roughly within a 2- to 4-fold range for the 24h 
excretion and overnight samples and within a 4- to 10-fold range for 
all spot urine samples. Meanwhile, 95% of the participants had a 
urinary cadmium excretion roughly within a 4- to 10-fold range; that 
is, highly exposed individuals had 4-10 times higher exposure 
compared to low-exposed individuals. 
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Since time point of sampling was an important determinant for urinary 
cadmium excretions in the spot urine samples (see section 4.4), mean 
urinary cadmium excretions were calculated as geometric means of 
arithmetic means per individual for the six sampling times (Figure 6) 
(Paper IV).  
 
 
Figure 6. Urinary cadmium concentrations (unadjusted and adjusted for diuresis) 
and excretion rates for different sampling times. Geometric means of individual 
arithmetic means (of two days) for 24 participants and 48 samples per time point 
(Paper IV, Figure 1).  
All measures of urinary cadmium excretion showed a circadian 
rhythm, with higher excretion during the daytime (especially in the 
second morning sample) compared to overnight. Similar results were 
also seen for the urinary flow rate, urinary albumin, and urinary alpha-
1-microglobulin, although albumin had a more stable excretion during 
the daytime (Paper IV, Figure 1). Time point of sampling was still a 
significant factor (p<0.001), for all measures of cadmium in urine, 
when other determinants such as gender, age, urinary flow rate, and 
urinary protein excretion were included in the mixed-effect models 
(Model 1B, Equation 2). Compared to the overnight sample, urinary 
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cadmium excretion was generally significantly higher in the second 
morning sample (09:30) and significantly lower in the afternoon and 
evening samples (14:30, 17:30, and 22:00) (Paper IV, Table 2). 
Calculations of group sizes (Paper IV) 
The results showed that at least two repeated samples per individual 
were required in an individually-based study of exposure-response 
relationship when using measures of urinary cadmium excretion in 
spot urine samples (Equation 3). Alternatively, one sample per 
individual was sufficient when measures of urinary cadmium excretion 
in 24h or overnight samples were used (Paper IV, Figure 3). 
 
For studies aimed at comparing cadmium levels between groups, 24h 
urinary cadmium excretion required the smallest group sizes (Equation 
4), but apart from this there were no substantial differences between 
the measures in spot urine or overnight urine samples (Paper IV, Table 
4). The number of individuals per group depended strongly on the size 
of the difference, with about 10 individuals per group needed to detect 
a difference of 100% and about 500 individuals for a difference of 
10%. Separate calculations on men and women showed that the 
number of individuals needed per group was lower for men than for 
women (Paper IV, Supplementary Information). The number of 
repeated samples per individual in the groups had only a small effect 
on the group sizes (Paper IV, Table 4).  
4.8 Associations between 24h urine 
cadmium excretion and concentrations 
in spot urine and blood samples   
(Paper I) 
There were significant correlations (p<0.001) between the 24h urinary 
cadmium excretion and all measures of urinary cadmium excretion in 
overnight samples among study participants with a kidney biopsy in 
study population 1 (urinary cadmium excretion rate: rp= 0.84, urinary 
cadmium concentration adjusted for creatinine: rp= 0.75, and urinary 
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cadmium adjusted for specific gravity: rp= 0.74). The 24h urinary 
cadmium excretion was also associated with blood cadmium (rp= 0.48, 
p<0.001), but not among never-smokers (Paper I). 
4.9 Effects of urinary flow rate, urinary 
creatinine excretion, and specific 
gravity on cadmium measures in urine 
(Papers II-IV). 
For study population 2, urinary flow rate was a significant determinant 
of most urinary cadmium measures in mixed-effect models (Equation 
2) but not for 24h urinary cadmium excretion (Paper IV, Tables 2-3). 
No effect of urinary flow rate on the urinary cadmium excretion rate 
was found in 24h urine and overnight urine samples in study 
population 1 (Paper III).  
 
The overall mean values for the association between urinary flow rate 
and urinary cadmium concentration adjusted for creatinine 
concentration were not significant, when investigated within study 
participants in study population 2 (Paper II). However, a significant 
positive association was seen between urinary flow rate and urinary 
cadmium concentration adjusted for specific gravity. There was also a 
significant positive overall mean value for the association between 
urinary flow rate and urinary creatinine excretion rate (overall mean 
rs= 0.25, overall mean regression coefficient= 0.25 × 10
-3
, p<0.001). 
Nevertheless, exclusion of very diluted or concentrated samples in 
Paper II did not change the overall result. 
 
A positive association was seen between urinary flow rate and the 
urinary creatinine excretion rate in overnight urine samples in study 
population 1, as reported in a publication, not included in this thesis 
(Akerstrom et al. 2012). The association was mainly seen at low 
urinary flow rates (regression coefficient=1.1, p<0.001 for urinary 
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flow rates < 42 mL/min and regression coefficient=0.03, p=0.7 for 
urinary flow rates ≥ 42 mL/min) but not in the 24h urine samples. 
 
When the association between the urinary cadmium concentration 
adjusted for creatinine concentration and the creatinine concentration 
was investigated within study participants of study population 2 (Paper 
II), a negative association was found (overall mean rs= -0.20, p=0.02 
and overall mean regression coefficient=-0.02, p=0.07). In contrast, 
specific gravity was not significantly associated with specific gravity-
adjusted urinary cadmium concentrations within the study participants.  
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5 DISCUSSION 
This thesis focuses on the application and interpretation of biomarkers 
of cadmium exposure in populations with environmental low-level 
cadmium exposure, with a special reference to studies of kidney 
effects. The importance of this lies in the fact that many studies are 
performed among populations with low-level exposures, rather than 
the high-exposure groups on which most current knowledge is based.  
 
Our studies are the first to provide empirical data on the relationship 
between cadmium in kidney and cadmium in urine and blood, and on 
the biological half-time of cadmium in the human kidney, using data 
from healthy living individuals with low-level cadmium exposure. Our 
data make it possible to study factors affecting the relationship 
between cadmium in kidney, urine, and blood, and factors affecting the 
excretion of urinary cadmium. We also offer one of only a few studies 
focusing on the effect of within- and between-individual variance on 
the study design when biomarkers of cadmium exposure are used. 
5.1 Cadmium in kidney, urine, and blood 
for individuals with a low-level 
environmental exposure 
When biomarkers are used in epidemiologic studies and for risk 
assessments, information on excretion of the biomarker and the 
association between the biomarker and the target organ/body burden is 
needed for both high and low levels of exposure. In an epidemiological 
study, it is also important to control for potential confounders; that is, 
factors that will affect both the measured biomarker and the studied 
outcome. Knowledge of factors that will affect the excretion of the 
biomarker (i.e. determinants) is therefore important. 
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Relationship between kidney cadmium and cadmium in 
urine and blood 
The kidney cadmium concentration was compared to the measures of 
cadmium in urine and blood (study population 1, Paper I), since this is 
what most risk assessments are based on. The strength of this 
relationship also gives a measure of the performance of these measures 
as biomarkers for cadmium body burden. The results showed relatively 
close relationships between kidney cortex cadmium and cadmium both 
in urine and blood, and these associations were highly significant 
(rp=0.44-0.70 for urine, rp=0.44 for blood; Paper I, Table 2). This 
indicates that all studied measures of cadmium in urine and blood 
represent the kidney cadmium or the body burden of cadmium 
relatively well at these low levels of cadmium exposure.  
 
Similar results on environmentally exposed individuals have been 
shown for kidney cadmium and urinary cadmium in two different 
autopsy studies (rp=0.85 and rp=0.58) (Orlowski et al. 1998; Satarug et 
al. 2002), and for kidney cadmium and blood cadmium in two different 
in vivo studies (rs=0.49 and rs=0.33) using X-ray fluorescence (Nilsson 
et al. 2000; Nilsson et al. 1995). However, in vivo measurements using 
X-ray fluorescence or neutron activation have historically failed to 
show a significant association between kidney cadmium and urinary 
cadmium in environmentally exposed individuals (Nilsson et al. 2000; 
Nilsson et al. 1995). This might be explained by a high limit of 
detection for kidney cadmium in these analytical techniques. The 
minimum detectable concentration for the X-ray fluorescence 
measurements was about 15 µg/g at a typical kidney depth, which is 
similar to the median kidney cadmium level in our study. Similarly, the 
neutron activation measurements had a minimum detectable amount of 
2500 µg as compared with the median kidney cadmium amount of 
3400 µg in our study. 
 
Risk assessments for kidney effects of cadmium, based on other 
biomarkers of cadmium exposure than kidney cadmium, require 
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knowledge of the quantitative relationships between kidney cadmium 
and these biomarkers. Previous to our study, researchers have 
estimated that a kidney cortex cadmium concentration of 25 µg/g 
corresponds to an overnight urinary cadmium concentration adjusted 
for creatinine of 1.25 µg/g creatinine (i.e. a urinary cadmium to kidney 
cadmium ratio of 1:20) (EFSA 2009; Järup et al. 1998; Nordberg et al. 
2007). Our estimate based on study population 1 (Paper I), with a 
median kidney cortex cadmium level of 15 µg/g, was considerably 
lower. A urinary cadmium concentration of 0.42 µg/g creatinine 
corresponded to a kidney cortex cadmium concentration of 25 µg/g, 
giving a urinary cadmium to kidney cadmium ratio of 1:60. 
Consequently, the current risk assessment underestimates the kidney 
cadmium level for populations with a low-level cadmium exposure.  
 
A possible reason for the much higher urinary to kidney cadmium ratio 
in the literature (1:20) might be that it is based on individuals with 
kidney cadmium levels high enough to cause an increased “leakage” of 
urinary cadmium due to renal cadmium toxicity. Another possible 
explanation is that the urinary cadmium levels in those studies were 
overestimated due to analytical limitations or post-mortem changes. 
There is also some previous evidence of dose-dependence in the 
kinetics of cadmium (Engström and Nordberg 1979; Järup et al. 1998). 
However, even results from the in vivo X-ray fluorescence studies on 
environmentally exposed individuals indicate a much lower urine to 
kidney cadmium ratio than 1:20, in agreement with our findings, if all 
participants with kidney cadmium below the minimum detectable 
concentration are taken into account (Nilsson et al. 2000; Nilsson et al. 
1995).  
 
The shape of the relationship between kidney cadmium and urinary 
cadmium was investigated in study population 1 (Paper I) using the 
total amount of cadmium in the kidney and the 24h urinary cadmium 
excretion, as these measures most likely represent the long-term 
cadmium burden more reliably than the kidney cortex concentration 
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and the cadmium concentration in spot urine samples (Nawrot et al. 
2010; Nordberg et al. 2007).  
The results showed a nonlinear relationship, with a relatively higher 
excretion of urinary cadmium at lower kidney cadmium concentrations 
compared to higher kidney cadmium concentrations. It might be 
explained by the dose-dependent cadmium kinetics mentioned above 
(Engström and Nordberg 1979; Järup et al. 1998), with a longer 
cadmium retention at higher kidney cadmium levels. This nonlinearity 
could also be an effect of factors other than kidney cadmium that may 
affect the urinary cadmium excretion (urinary proteins and recent 
cadmium exposure, discussed more in detail below), which will have a 
relatively stronger effect at lower cadmium levels. A nonlinear 
relationship might have an effect on pharmacokinetic modelling (often 
used in risk assessments), calculations of the biological half-time, and 
the interpretation of very low urinary cadmium levels. 
Elimination and biological half-time of cadmium in kidney 
at environmental low-level exposures 
The elimination constant of cadmium in kidney was estimated in study 
population 1 (Paper I) as the regression coefficient between the 
amount of cadmium in the kidney and the 24h urinary cadmium 
excretion. The fraction of the total amount of cadmium in the kidney 
excreted in urine over 24h was estimated at 0.009% using a model 
without an intercept; and 0.006% using a model with an intercept, in 
agreement with previous findings (EFSA 2009; Nordberg et al. 2007). 
When the data were stratified for kidney cadmium concentration, to 
account for the nonlinear relationship between kidney cadmium and 
urinary cadmium, the estimates were 0.011% for low kidney cadmium 
levels (<15 µg/g) and 0.007% for higher levels.  
 
The elimination coefficients were used to estimate the biological half-
time of cadmium in kidney, assuming a one-compartment model 
(Equation 1). We estimated the half-time to be about 30 years at a 
typical kidney cortex concentration of 15 µg/g. Using different models 
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gave half-times between 18 and 30 years when linear models were 
used, while a nonlinear model gave biological half-times between 21 
and 44 years in our range of data. Our estimate of a 30-year biological 
half-time of cadmium in kidney is in the higher range compared to 
previous estimates (EFSA 2009; Järup et al. 1998; Nordberg et al. 
2007).  
Determinants for urinary cadmium excretion 
We studied several different determinants for urinary cadmium 
excretion in both study population 1 (Paper 1) and study population 2 
(Paper IV).  
 
In addition to kidney cadmium, determinants such as blood cadmium, 
urinary protein excretions, age, and gender were included in a 
multivariate model for the 24h urinary cadmium excretion in study 
population 1 (Paper I). The final model, derived by step-wise 
backwards elimination, showed that about 70% of the urinary 
cadmium excretion could be explained by kidney cadmium for an 
average individual with a kidney cadmium concentration of 15 µg/g 
and a 24h urinary cadmium excretion of 0.31 µg/24h. The remaining 
30% was explained by blood cadmium levels, urinary protein 
excretion, and other determinants. 
 
Study population 1 (Paper I) included some smokers. As expected, 
smoking status (ever- vs. never-smokers) was a significant determinant 
for urinary cadmium excretion, as reported by other researchers 
(Adams et al. 2011; EFSA 2009; Ikeda et al. 2005; Järup et al. 1998; 
Nordberg et al. 2007; WHO 2011). Blood cadmium was also a 
significant determinant for urinary cadmium, especially for smokers 
and for participants with a kidney cadmium concentration above 15 
µg/g. However, the additional impact of blood cadmium on the urinary 
cadmium excretion still represents renal clearance of cadmium. Blood 
cadmium is assumed to increase more than kidney cadmium after the 
short-term cadmium exposure which occurs in smokers. In these cases, 
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blood cadmium might also equilibrate with compartments with faster 
turnover of cadmium than the kidney compartment. Thus, when blood 
cadmium is high and a steady state of kidney cadmium has not been 
reached (which may be the case in smokers below 50 years of age), a 
fraction of the cadmium filtered in the glomeruli may be excreted 
rather than reabsorbed. In agreement with our findings, this impact of 
blood cadmium on urinary cadmium excretion, over and above the 
impact of kidney cadmium, has been predicted in metabolic models of 
cadmium in humans (Kjellström and Nordberg 1978). 
 
An effect of urinary protein excretion (mainly urinary albumin) on 
urinary cadmium excretion was found in both study populations 
(Papers I & IV), a result also reported by others both prior to and after 
our studies (Chaumont et al. 2012; Chaumont et al. 2013; Haddam et 
al. 2011). In study population 1 (Paper I) the effect was mainly seen 
for never-smokers and individuals with a kidney cortex cadmium 
concentration below 15 µg/g, but in study population 2 (Paper IV) the 
effect was seen for most urinary measures of cadmium exposure in 
overnight and spot urine samples. This association probably represents 
normal variability in renal physiology, resulting in temporarily 
increased or decreased cadmium excretion independent of kidney 
cadmium (Bernard 2008; Chaumont et al. 2012; Chaumont et al. 2013; 
Haddam et al. 2011; Åkesson et al. 2014). The excretion of cadmium 
and proteins is assumed to change in the same direction, since 
cadmium bound to metallothionein and proteins such as albumin share 
the same tubular binding site (Christensen et al. 2009); this results in 
an association between the two during temporary changes in the renal 
physiology. 
 
Gender and age were significant determinants for urinary cadmium for 
most cadmium measures in urine in study population 2 (Paper IV). 
This is as expected, since women generally have a higher cadmium 
absorption because of low iron stores (Berglund et al. 1994; Flanagan 
et al. 1978; Julin et al. 2011; Vahter et al. 1996), and cadmium 
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accumulates with age because of the long half-time of cadmium in the 
human body (EFSA 2009; Järup et al. 1998; Nordberg et al. 2007; 
WHO 2007). In study population 1 (Paper I), where other 
determinants such as kidney and blood cadmium were included in the 
multivariate models, the effects of gender and age were mainly seen 
among smokers. 
 
We also found an effect of urinary flow rate and time point of 
sampling on urinary cadmium excretion, especially in spot urine 
samples, among the repeated samples from study population 2 (Paper 
IV). An effect of urinary flow rate indicates that the adjustment for 
diuresis was imperfect, as discussed by others (Berlin et al. 1985; 
Chaumont et al. 2013; Elkins et al. 1974; Greenberg and Levine 1989; 
Suwazono et al. 2005). An effect of the time point of sampling 
indicates a circadian rhythm in the urinary cadmium excretion which 
will be discussed below. 
5.2 The interpretation of cadmium 
measured in urine and effects on 
current risk assessments for kidney 
effects 
When choosing a biomarker for cadmium exposure, it is important to 
consider not only information regarding the association between the 
biomarker and the target organ/body burden, but also information 
concerning the interpretation of a biomarker and factors affecting the 
interpretation under certain circumstances. For studies of kidney 
effects, measured as an increased urinary excretion of proteins, such 
information is vital since both the cadmium exposure and kidney effect 
are measured in the same urine sample. Thus, factors affecting the 
urinary cadmium excretion might also affect the urinary protein 
excretion. 
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Urinary cadmium as a biomarker in studies of kidney 
effects  
The interpretation of urinary cadmium as a biomarker for cadmium 
exposure in epidemiological studies of kidney effects, at a low level 
cadmium exposure, was investigated by studying the association 
between urinary cadmium and urinary proteins within study 
participants in study population 2 (Paper II). Urinary protein excretion 
was also included as a determinant for the urinary cadmium excretion 
in Paper I.  
 
Within the participants of study population 2 (Paper II), an association 
between urinary cadmium and urinary proteins was seen for all urinary 
measures. The association remained for most urinary measures even 
after the inclusion of more determinants (Papers I & IV). Because 
cadmium has a long biological half-time in the human body (EFSA 
2009; Järup et al. 1998; Nordberg et al. 2007), the cadmium body 
burden is expected to be stable over two sampling days (mostly within 
one week), and urinary cadmium should only be affected by normal 
physiological variations. Thus, the association observed within 
participants in our study (Paper II) is not consistent with an effect of 
cadmium toxicity on the kidney.  
 
Such an association has also been observed at low-level cadmium 
exposures in other study populations previously (Chaumont et al. 
2012; Haddam et al. 2011) and later (Chaumont et al. 2013), and has 
been associated with temporal changes in renal physiology, since 
urinary cadmium bound to metallothionein and urinary proteins such 
as albumin share the same binding site (Chaumont et al. 2012). The 
association has been proposed to be driven largely by smoking 
(Haddam et al. 2011). However, we found an association among never-
smokers, regardless of how the spot urine samples were adjusted for 
diuresis, and thus the association could not be explained by smoking 
only. We also found an effect of urinary flow rate for most urinary 
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measures of cadmium, suggesting that urinary flow is an important 
determinant for the variation in tubular reabsorption (Paper II).  
These results indicate that caution is needed if urinary cadmium is used 
as a biomarker of exposure when studying renal effects of cadmium 
toxicity at low-level cadmium exposures. Studies that have used 
urinary cadmium as a biomarker for cadmium exposure, when 
studying kidney effects, might have overestimated the risk of kidney 
effects from cadmium toxicity at low cadmium exposures. 
Short-term variability within and between individuals and 
effects on the interpretation of urinary cadmium 
Using mixed-effects models on the repeated samples from study 
population 2 (Paper IV), the short-term variability within and between 
individuals was studied for the available measures of cadmium in 
urine. This variability may lead to a biased prediction if urinary 
cadmium is used as a biomarker for cadmium exposure in 
epidemiologic studies or studies comparing exposure levels between 
groups. 
 
The between-individual variability dominated the total variability for 
most measures of cadmium in urine (ICCs between 0.39 and 0.89), 
indicating a close relationship between the biomarker of exposure and 
differences in exposure level between individuals (Rappaport and 
Kupper 2008). A review on biomonitoring of occupational exposures 
drew a similar conclusion regarding biomarkers with long biological 
half-times (Symanski and Greeson 2002). The ratio between the 
within- and between-individual variability decreased (on average a 
decrease of about 50%) when urinary cadmium was adjusted for 
dilution and when overnight and 24h urine samples were chosen before 
spot urine samples (on average about 70%). This indicates a larger 
reproducibility for these biomarkers, which demonstrates the need for 
adjusting spot urine samples for dilution and for the use of time-
specific sampling such as the collection of overnight urine samples in 
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studies. The latter point was also stressed by the finding of a circadian 
rhythm in urinary cadmium excretion (Paper IV). 
 
Previous studies have reported a reduction of the variance when 
adjusting urinary cadmium concentrations for dilution (Arisawa et al. 
1997; Mason et al. 1998; Yamagami et al. 2008). In our study, this was 
the case for urinary cadmium concentrations adjusted for creatinine in 
overnight samples, but not for the cadmium concentrations adjusted for 
specific gravity. However, adjustment for dilution increased the ICC 
for all measures (Paper IV).  
 
Only a few studies have investigated the short-term within-individual 
variability of urinary cadmium, and most of them had longer time 
intervals between the collected urine samples compared to our study. A 
similar within-individual variation in urinary cadmium concentrations 
adjusted for dilution was seen in second morning samples taken over 
10 sequential weeks among 17 environmentally exposed women in 
Japan (Yamagami et al. 2008). However, a study with repeated urine 
samples taken three months apart found a substantially lower ICC for 
urinary cadmium compared to our study (Gunier et al. 2013). 
 
As indicated above, we found a significant circadian rhythm in urinary 
cadmium excretion over 24h (Paper IV). Such circadian rhythm has 
also been seen by others (Kanabrocki et al. 2008). In mixed-effects 
models, the time point of sampling was found to be a significant 
determinant of urinary cadmium in spot urine samples. When the 
different sampling times were compared to each other, the urinary 
cadmium excretion was generally significantly higher in the second 
morning sample (09:30) and significantly lower in the afternoon 
samples (14:30, 17:30 and 22:00) compared to overnight samples. 
 
Factors such as urinary protein excretion or urinary flow rate could 
partly but not fully explain the variation in urinary cadmium excretion 
over 24h when included in multivariate models. Another possible 
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factor that might affect urinary cadmium excretion (as well as protein 
excretion and urinary flow) is circadian variations in the kidney 
function. Such circadian rhythm was seen in glomerular filtration rate 
and renal plasma flow in a study of 11 healthy individuals during bed 
rest and standardized protein intake (Koopman et al. 1989). The 
glomerular filtration rate was found to be higher during the daytime 
compared with overnight, and the urinary flow rate was found to have 
the same circadian rhythm as the glomerular filtration rate (Koopman 
et al. 1989). A study of occupationally exposed workers revealed a 
decreased urinary cadmium excretion overnight, which the authors 
attributed to the glomerular filtration rate (Yokoyama et al. 2000). A 
significant effect of glomerular filtration rate on urinary cadmium 
excretion was also found among 19 occupationally exposed individuals 
using water loading and water restrictions (Araki and Aono 1989), and 
among lead workers (Weaver et al. 2011). 
 
Consequently, even though cadmium has a long biological half-time in 
humans, resulting in a stable long-term cadmium level, the short-term 
variations in urinary cadmium excretions caused by natural 
physiological changes will still have an effect on the cadmium 
measured in urine, causing an attenuation of the epidemiological dose-
response relationship in a study of health effects. 
5.3 Aspects of the choice of biomarkers for 
cadmium body burden and sampling 
strategy 
Studies on low-exposure populations, as well as epidemiological 
studies on rare or subtle effects, place increased demands on the study 
design and choice of biomarker. If the exposure levels in an 
epidemiological study are not accurately characterized, the estimated 
relationship between exposure and health effects in humans (the 
estimated regression coefficient) tends to be underestimated 
(Rappaport and Kupper 2008). The performance of the biomarker also 
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affects the number of samples needed to achieve valid results in terms 
of a high power in the study (Li et al. 2010; Lin et al. 2005; Rappaport 
and Kupper 2008).   
Measurement strategy and analytical method 
Theoretically, urinary 24h cadmium excretion should represent the 
cadmium body burden most reliably, since this is the average excretion 
over a longer time (Nawrot et al. 2010; Nordberg et al. 2007). 
However, 24h urine samples are difficult to collect, and the high risk 
of incomplete and contaminated samples makes 24h sampling 
inappropriate for most epidemiological studies. Spot urine samples or 
blood samples are more feasible to collect in these kinds of studies. 
Therefore, overnight spot urine samples (first morning samples) and 
blood samples were compared to separate 24h urine samples collected 
under controlled circumstances (hospitalization) in Papers I & III. 
There was a strong association (rp>0.74, p<0.001) between the 
measures in overnight urine samples and the 24h urinary cadmium 
excretion (Paper I); this indicates that the overnight urine samples 
represent the 24h urinary excretion relatively well, as described 
previously by others (Berlin et al. 1985). Blood cadmium also 
represented the 24h urinary cadmium excretion relatively well 
(rp=0.48, p<0.001), but when the study population was stratified for 
smoking habits, the association was only present for smokers. 
Overnight urine samples and blood samples were also significantly 
associated with kidney cadmium, as discussed above. 
 
When the cadmium levels in 24h and overnight urine samples were 
compared within individuals in Paper III, significant differences were 
found between the two samples, indicating that the measurement 
strategy will affect the results, and thus comparisons within and 
between studies require similar measurement strategies. 
 
Further investigation in study population 2 (Paper IV) showed a 
significant circadian rhythm even during the daytime for most 
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cadmium measures in spot urine samples. It is therefore clear that a 
specific time point of sampling must be used if results are to be 
compared within and between studies. The best time point would be 
overnight samples (first morning samples), since the conditions tend to 
be more stable overnight. Additional evidence for this need for 
consistency in time of sampling is provided by the investigation of 
variability in Paper IV, with its comparison between spot urine 
samples and time-specific samples (overnight urine samples). When 
cadmium measures in overnight urine samples were used instead of 
spot urine samples collected throughout the day, the ICC increased and 
the total variability decreased for most urinary cadmium measures. 
 
In Paper III, we showed the importance of correcting urinary cadmium 
concentrations for molybdenum oxide-based interference if certain 
ICP-MS techniques are used, since this interference greatly affects the 
interpretation of the results. 
Adjusting urinary concentrations in spot urine samples 
for dilution 
Spot urine samples need to be adjusted for dilution. In the present 
thesis, this was achieved by calculating the cadmium excretion rate or 
by adjusting the cadmium concentration for urinary creatinine 
concentration or specific gravity. Numerous studies have investigated 
the optimal adjustment method for cadmium concentrations in spot 
urine, with inconsistent results (Araki and Aono 1989; Berlin et al. 
1985; Carrieri et al. 2001; Elkins et al. 1974; Greenberg and Levine 
1989; Mason et al. 1998; Pearson et al. 2009; Sata et al. 1995; 
Suwazono et al. 2005). Our results showed only moderate differences 
in the performance of the different adjustment methods used in this 
thesis. However, adjusting the cadmium concentration using the 
urinary creatinine concentration (i.e. the cadmium to creatinine 
concentration ratio) would be the best choice when adjusting cadmium 
concentrations in spot urine samples for dilution, see below. 
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When adjusting for creatinine concentration, a constant excretion of 
urinary creatinine is assumed. However, there is evidence showing that 
adjusting for cadmium concentration using creatinine concentration is 
not a perfect method. In study population 1, the urinary creatinine 
excretion was affected by the urinary flow rate (Akerstrom et al. 2012), 
a phenomenon also demonstrated by others (Greenberg and Levine 
1989; Trachtenberg et al. 2010). In Paper II, urinary flow rate was a 
significant determinant for urinary cadmium within individuals even 
after adjusting for creatinine, and significant correlations were found 
between the urinary cadmium concentration adjusted for creatinine and 
the urinary creatinine concentration. Nevertheless, urinary cadmium 
concentration adjusted for creatinine showed a somewhat stronger 
association with kidney cadmium compared to the other measures of 
cadmium in urine (Paper I, Table 2 & Figure 2). Urinary cadmium 
concentration adjusted for creatinine was also less affected by normal 
physiological variations compared to cadmium concentrations adjusted 
for specific gravity or cadmium excretion rates (Paper II).  
 
Adjustment for dilution reduced the variance when the cadmium 
concentration was adjusted for creatinine, but not when specific 
gravity was used. Urinary cadmium concentrations adjusted for 
creatinine also had somewhat higher reproducibility (i.e. higher ICC) 
compared to cadmium concentrations adjusted for specific gravity 
(ICC=0.89 vs. ICC=0.75, Paper IV). In addition, using urinary 
cadmium concentrations adjusted for creatinine concentration 
reproduced the gender difference (Papers I, III, & IV) seen in kidney 
cadmium (Barregard et al. 2010). 
 
The cadmium excretion rate performed generally well and required 
somewhat smaller study sizes compared to urinary cadmium 
concentrations adjusted for creatinine (Paper IV, discussed more 
below) but these small differences might not justify the extra work 
involved in collecting timed urine samples in a study.  
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Appropriate sample size when using urinary biomarkers 
for cadmium exposure 
When planning a study, the appropriate sample size required to obtain 
valid results is of great importance. The optimal sample size in a study 
is reached when a high accuracy can be achieved (preferably a bias of 
20% or lower) with a reasonable number of samples to collected. The 
optimal sample size might vary depending on the choice of measure of 
cadmium exposure and the choice of sampling strategy. Our results 
indicate that different study types place different demands on the 
measures of cadmium in urine and the sampling strategy. Thus, the 
choice of biomarker for cadmium exposure and the choice of sampling 
strategy in a study will affect the optimal sample size.  
 
In epidemiological individually-based studies where dose-response 
relationships are studied, the relation between the within- and between-
individual variability is important for achieving a high accuracy in the 
estimated regression slope. According to Equation 3, the accuracy can 
also be increased by increasing the number of samples per individual 
in a study. Paper IV showed that choosing a specific time point of 
sampling, such as overnight urine samples, increases the ICC for all 
cadmium measures and thus decreases the required number of repeated 
measurements per individual to one. Consequently, if only spot urine 
samples taken throughout the day are accessible in a study, a single 
measurement of urinary cadmium per individual does not seem to be 
sufficient to achieve a bias of 20% or less. Among a group of women 
who each provided two 24h urine samples (3-9 months apart), four 24h 
urine samples per participant were required to achieve the same power 
(Gunier et al. 2013).  
 
In studies comparing the cadmium exposure level between two groups, 
the number of samples per individual did not have a large effect on the 
group sizes, indicating that a high study power would be better 
achieved by increasing group sizes than by increasing the number of 
repeated samples per individual (Paper IV). This has also been shown 
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for urinary proteins (Stengel et al. 1999). In this kind of study, the 
most important factor affecting the required sample size is the 
expected difference between the two groups compared. It is therefore 
crucial to make a prior estimate of the expected difference, since going 
from a 50% difference between the two groups to a 25% difference 
results in a threefold increase in the required sample size. It is also 
important to remember that a strong gender difference was seen in 
Paper IV (Supplementary Information), with a larger variability among 
women, meaning that much larger group sizes are required if studies 
are carried out among women only. The larger variance may be caused 
by differences in iron status (Berglund et al. 1994; Flanagan et al. 
1978; Julin et al. 2011; Vahter et al. 1996) and/or other factors 
affecting women more than men. 
5.4 Validity and generalizability 
Neither of the two study populations was randomly selected from the 
environmentally exposed population, due to ethical and/or practical 
reasons. Nevertheless, we believe that they are representative for the 
healthy part of the environmentally low-level exposed population 
without exposure from any industrial sources, in terms of the aspects 
studied in this thesis. Study population 1 included never- and ever-
smoking men and women aged 24-70. Personal information was 
collected for all participants, and only two participants were found to 
have had a low occupational cadmium exposure in the past. Although 
all kidney donors were recruited at the transplantation unit, we believe 
that they represent the environmentally exposed population with regard 
to the relationship between cadmium in kidney, urine, and blood.  
 
Study population 2 was recruited from our department and among 
students at the university, and consisted of never-smoking men and 
women aged 23-59. Compliance with the extensive urine sample 
collection schedule was of great importance for this study, and so the 
study participants were not randomly selected. Background 
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information was collected for each study participant, and no one was 
found to have a present or past occupational exposure to cadmium. The 
study population might have had a more sedentary work compared to 
the entire environmentally exposed population, but we do not think 
that either urinary excretion itself or variability in cadmium and 
protein excretion will be affected by physical activity. A very small 
pilot study performed at our department gave no indication of an effect 
of physical activity on cadmium excretion (data not shown). However, 
in a study comparing 21 professional athletes to 26 sedentary 
individuals, an increased urinary cadmium excretion was found among 
the group of athletes (Llerena et al. 2012).  
 
Although neither study population was randomly selected from the 
general population, their level of cadmium exposure corresponds well 
to the low-level environmentally exposed general population 
(Barregard et al. 2010; EFSA 2009; Järup et al. 1998; Nordberg et al. 
2007; Sand and Becker 2012; WHO 2007).  
 
A higher number of study participants generally improves the ability to 
achieve valid results. Study population 1 consisted of 152 participants, 
109 of whom had a kidney biopsy available for cadmium analysis. 
This makes this study considerably larger than other studies of the 
relationship between cadmium in kidney, urine, and blood among the 
environmentally exposed population (Nilsson et al. 2000; Nilsson et al. 
1995; Orlowski et al. 1998; Satarug et al. 2002). Study population 2, 
consisting of 30 participants (all never-smokers), was also larger than 
in other studies of mechanisms such as circadian rhythms (Araki et al. 
1986; Koopman et al. 1989; Yokoyama et al. 2000). 
 
Since two different study populations were used in this thesis, some of 
the aspects of interest, including determinants for urinary cadmium 
excretion and the circadian rhythm of urinary cadmium excretion, 
could be studied in both study populations. In these cases, similar 
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results were found for both study populations, which strengthens the 
findings. 
 
When studying small effects at low levels of the biomarkers, the 
accuracy of the chemical analyses is of great importance. All cadmium 
analyses were performed together with external quality control 
samples, with satisfactory results. In addition, the urinary cadmium 
concentrations in study population 1 were reanalysed in Paper III, and 
the samples that had been corrected for molybdenum oxide-based 
interference both times agreed strongly with the initial analysis. 
 
Another potential problem when analysing low-level exposures is 
values below the limit of detection. In study population 1 (Papers I & 
III), only a few values were below the limit of detection, and these 
were estimated according to the distribution of the data (Hornung and 
Reed 1990). For study population 2 (Papers II & IV), a higher 
percentage of the urinary cadmium concentrations were below the limit 
of detection. The values were estimated in the same way as for study 
population 1, but when studying variability (Paper IV), individuals 
with 50% or more of their urinary cadmium concentrations below the 
limit of detection were excluded to minimize the potential risk of 
attenuating the total variability. The kidney cadmium concentration 
was determined from a small biopsy, and hence an uneven distribution 
of cadmium in the kidney could potentially introduce some bias. 
However, all biopsies were classified as representative of the kidney 
cortex by an experienced pathologist, and the geometric standard 
deviation of the kidney cortex concentration was similar to results in 
autopsy studies with larger biopsies (Barregard et al. 2010). The 24h 
urine samples from study population 1 were collected at the hospital, 
which we believe improved the quality of these otherwise difficult-to-
collect samples. 
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6 CONCLUSIONS 
 There was a strong but nonlinear association between urinary 
cadmium and kidney cadmium, with slower elimination of 
cadmium at high kidney cadmium. The association between 
cadmium in blood and kidney cadmium was weaker. A kidney 
cadmium of 25 µg/g corresponded to a urinary cadmium of 
0.42 µg/g creatinine (a urinary cadmium to kidney cadmium 
ratio of 1:60). Previous estimates of the urinary cadmium to 
kidney cadmium ratio may underestimate kidney cadmium at 
low urinary cadmium. 
 
 Aside from kidney cadmium, cadmium in blood and urinary 
albumin were significant determinants for urinary cadmium 
excretion in multivariate models. Kidney cadmium explained 
about 70% of the urinary cadmium excretion for an average 
participant. 
 
 Between 0.007% and 0.011% of the total kidney cadmium 
burden was excreted in urine over 24h. The biological half-time 
of cadmium in kidney was estimated to be about 30 years. 
  
 Significant associations between urinary cadmium and urinary 
proteins were found within participants at low urinary cadmium 
levels, indicating that this association is caused by normal 
physiology rather than renal toxicity. Consequently, the risk of 
kidney damage may be overestimated at low urinary cadmium 
levels. 
 
 Molybdenum oxide-based interference can result in an 
overestimation of cadmium concentrations when urinary 
cadmium is analysed using certain ICP-MS techniques. Thus, 
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correction for molybdenum oxide-based interference may be 
needed when urinary cadmium is analysed in this way. 
 
  Between-individual variability dominated the total variability 
for most measures of urinary cadmium excretion. Urinary 
cadmium excretion showed a circadian rhythm during the day, 
and time point of sampling was a significant factor even after 
more determinants had been included in the models. 
 
 In terms of achieving a high power with a limited number of 
samples, the choice of biomarker for urinary cadmium 
excretion was found to be more important in individually-based 
studies of exposure-response relationships than in studies 
comparing cadmium levels of different groups. 
 
 Samples from first morning urine represent both kidney 
cadmium and 24h urinary excretion of cadmium relatively well 
and are feasible to use in larger studies. Cadmium 
concentrations adjusted for dilution using creatinine 
concentration or specific gravity generally perform well, but 
our results indicate that cadmium concentrations adjusted for 
creatinine are less influenced by urinary protein excretion and 
result in a slightly higher accuracy in individually-based studies 
of exposure-response relationships. 
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7 FUTURE RESEARCH 
This thesis contributes new knowledge about cadmium biomonitoring 
at low-level cadmium exposure, using studies carried out on two 
different Swedish study populations with comparatively very low 
environmental cadmium exposure. The results still need to be verified 
for a wider range of cadmium exposures, to establish the range of data 
on which these results can be applied. This is particularly important for 
the results that differ from existing estimates derived from populations 
with higher exposure levels; that is, the relationship between urinary 
cadmium and kidney cadmium and the association between urinary 
proteins and urinary cadmium.  
By using this new data, it should also be possible to update the 
metabolic model of cadmium in humans created by Kjellström and 
Nordberg (1978). 
In recent years, cadmium exposure has been assessed by the use of 
food questionnaires. There is a need for more data on the relationship 
between these dietary assessments of cadmium intake and biomarkers 
of cadmium in blood and urine. 
The studies described in this thesis, especially Paper IV, show that the 
short-term variability of urinary cadmium excretion should affect the 
study design. Our results are based on healthy non-smoking 
individuals with mainly sedentary work, and more studies need to be 
done to provide additional data on other populations, including 
smokers. 
The determinants available in these studies could not fully explain 
either the circadian rhythm in urinary cadmium excretion (Papers III 
& IV) or the association between urinary cadmium and urinary proteins 
in the absence of an effect of cadmium toxicity (Papers I, II & IV). 
Different kinds of normal physiological variation have been presented 
as possible explanations, but there is a need for more studies 
identifying such natural variations and other factors which may be 
relevant for cadmium biomonitoring. 
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